Knowledge and perceptions about fragile X syndrome: implications for diagnosis, intervention, and research.

Finucane et al. (2013) sent a survey to 439 autism professionals. They asked how much the staff knew about fragile X syndrome and whether they ever asked about it during intake.

The survey covered BCBAs, teachers, speech therapists, and other team members. It checked basic facts like what causes FXS and why the gene matters for treatment.

Most respondents scored low on FXS knowledge questions. Fewer than half said they ever ask families if the child has been tested for fragile X.

Yet almost all agreed that knowing the cause would help them plan better lessons and behavior programs.

Acharya et al. (2013) ran a nearly identical survey the same year with developmental pediatricians and got the same result: low FXS know-how. The back-to-back studies show the gap is wide across job titles.

Tabatadze et al. (2025) later tested 441 Georgian children with ASD or ID and found that 1 in 17 actually had full FXS, but the diagnosis came 4.6 years after the first autism label. Brenda’s missing questions are part of that delay.

Diemer et al. (2023) screened Filipino children with ASD and found no full mutations, only intermediate alleles. This seems to clash with the Georgia numbers, but both studies agree on one point: you will not find FXS if you never test for it.

You cannot write an effective behavior plan if you miss the medical reason behind the behavior. Adding one line to your intake form—“Has your child had fragile X testing?”—takes seconds and can shave years off diagnostic delay. When results come back positive you can link the family to FXS clinics, targeted language therapy, and emerging drug trials while you keep running your ABA program.